Wuhan Hiteck Biological Pharma Co (SZSE:300683) Total Assets : ¥2,943.7 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Total Assets?

Wuhan Hiteck Biological Pharma Co's Total Assets for the quarter that ended in Sep. 2024 was ¥2,943.7 Mil.

During the past 12 months, Wuhan Hiteck Biological Pharma Co's average Total Assets Growth Rate was 15.90% per year. During the past 3 years, the average Total Assets Growth Rate was 8.30% per year. During the past 5 years, the average Total Assets Growth Rate was 17.90% per year. During the past 10 years, the average Total Assets Growth Rate was 24.30% per year.

During the past 11 years, Wuhan Hiteck Biological Pharma Co's highest 3-Year average Total Assets Growth Rate was 54.40%. The lowest was 7.00%. And the median was 26.15%.

Total Assets is connected with ROA %. Wuhan Hiteck Biological Pharma Co's annualized ROA % for the quarter that ended in Sep. 2024 was -2.30%. Total Assets is also linked to Revenue through Asset Turnover. Wuhan Hiteck Biological Pharma Co's Asset Turnover for the quarter that ended in Sep. 2024 was 0.06.

Wuhan Hiteck Biological Pharma Co Total Assets Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Total Assets Chart

Wuhan Hiteck Biological Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

2,175.86

2,194.07

2,697.51

2,706.86

2,971.25

Wuhan Hiteck Biological Pharma Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															2,926.87	2,971.25	2,965.34	2,964.40	2,943.66

Wuhan Hiteck Biological Pharma Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Wuhan Hiteck Biological Pharma Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	2495.521	+	475.73
	=	2,971.3

Wuhan Hiteck Biological Pharma Co's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	2453.531	+	490.133
	=	2,943.7

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Total Assets Explanation

Total Assets is connected with ROA %.

Wuhan Hiteck Biological Pharma Co's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-67.912	/	( (2964.396	+	2943.664)	/ 2 )
	=	-67.912	/	2954.03
	=	-2.30 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Wuhan Hiteck Biological Pharma Co's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	166.366	/	( (2964.396	+	2943.664)	/ 2 )
=	166.366	/	2954.03
=	0.06

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Wuhan Hiteck Biological Pharma Co Total Assets Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Total Assets

Traded in Other Exchanges

N/A

Address

Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056

Website

http://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Executives

Yan Jie	Director
Li Sheng Qiang	Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines